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Aims Combined left ventricular assist device (LVAD) and pharmacological therapy has been proposed
to favour myocardial recovery in patients with end-stage heart failure (HF). Clenbuterol (Clen), a b2-
adrenoceptor (b2-AR) agonist, has been used as a part of this strategy. In this study, we investigated
the direct effects of clenbuterol on unloaded myocardium in HF.
Methods and results Left coronary artery ligation or sham operation was performed in male Lewis rats.
After 4–6 weeks, heterotopic abdominal transplantation of the failing hearts into normal recipients was
performed to induce LV unloading (UN). Recipient rats were treated with saline (Sal) or clenbuterol
(2 mg/kg/day) via osmotic minipumps (HF þ UN þ Sal or HF þ UN þ Clen) for 7 days. Non-transplanted
HF animals were treated with Sal (Sham þ Sal, HF þ Sal) or clenbuterol (HF þ Clen). LV myocytes were
isolated and studied using optical, fluorescence, and electrophysiological techniques. Clenbuterol treat-
ment improved in vivo LV function measured with echocardiography (LVEF (%): HF 35.9+2 [16], HF þ
Clen 52.1+1.4 [16]; P , 0.001; mean+ SEM [n]). In combination with unloading, clenbuterol increased
sarcomere shortening (amplitude (mm): HF þ UN þ Clen 0.1+0.01 [50], HF þ UN þ Sal 0.07+0.01
[38]; P , 0.001) by normalizing the depressed myofilament sensitivity to Ca2þ (slope of the linear
relationship between Ca2þ transient and sarcomere shortening hysteresis loop during relaxation (mm/
ratio unit): HF þ UN þ Clen 2.13+0.2 [52], HF þ UN þ Sal 1.42+0.13 [38]; P , 0.05).
Conclusion Clenbuterol treatment of failing rat hearts, alone or in combination with mechanical
unloading, improves LV function at the whole-heart and cellular levels by affecting cell morphology,
excitation–contraction coupling, and myofilament sensitivity to calcium. This study supports the use
of this drug in the strategy to enhance recovery in HF patients treated with LVADs and also begins to








End-stage heart failure (HF) has a high incidence in the
community with a mortality of 45% after 1 year.1 Heart
transplantation is the most effective treatment for this
disease but is hindered due to an inadequate availability
of donor organs. Among other treatments, left ventricular
assist devices (LVADs) have been shown to be a suitable
alternative.2 LVAD support is primarily used as a ‘bridge to
transplantation’ where the failing heart can be supported
by mechanical circulatory assistance until a suitable donor
organ becomes available.3 In few patients, the LVAD also
acts as ‘bridge to recovery’ since it induces substantial func-
tional improvement that allows explantation of the device
without the need of transplantation.4 However, the rate
for explantation of the LVAD is low with an incidence of
only 4–24%.5–7 In addition, the functional improvement
observed during LVAD treatment seems to be a transient
phenomenon.7
The main consequence of the use of LVAD on the heart is
mechanical unloading leading to functional, structural, sig-
nalling, and molecular changes in HF.8 One important
effect is the development of myocardial atrophy with poss-
ible detrimental consequences. Mechanical unloading in
animal studies shows time-dependent changes in myocyte
contractile function and excitation–contraction (EC) coup-
ling9 that can impair cardiac performance after prolonged
treatment with LVADs.
We have recently shown that using a combination of
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to a substantially improved recovery rate in patients with
dilated cardiomyopathy.10,11 Together with other drugs,
the b2-adrenoceptor (b2-AR) agonist clenbuterol has been
included in the protocol with the aim to prevent
unloading-induced atrophy and consequent myocardial dys-
function. Clenbuterol is known to produce skeletal12 and
cardiac hypertrophy, to affect EC coupling and cellular
metabolism,13 gene expression and myocardial function14–16
in normal hearts. Clenbuterol has been shown to affect myo-
cardial structure, function, metabolism, gene and protein
expression at whole-heart and cellular level in normal,13–18
failing,12,19 and unloaded hearts.12,20 In the setting of the
successful combination of mechanical unloading and pharma-
cological therapy for the treatment of patients with HF, the
specific role of clenbuterol in the recovery process remains
controversial.
The pathological process involved in the development of
HF has been termed ‘ventricular remodelling’, a concept
relating to a complex of anatomic, functional, cellular,
and molecular changes that the myocardium undergoes in
response to the injury and increased wall stress.1 LVAD
support has been shown to affect and sometimes reverse
the remodelling process (‘reverse remodelling’).21 Whether
clenbuterol enhances the process of reverse remodelling in
unloaded failing hearts is unknown.
In the present study, we have investigated the role and
possible mechanisms of clenbuterol in enhancing reverse
remodelling during mechanical unloading in a murine
chronic HF model. Specifically, we have investigated the
effects of clenbuterol on whole-heart function, cell size,
EC coupling, myofilament sensitivity to Ca2þ, and electro-
physiological properties in a rat model of HF, induced by
left coronary artery (LCA) ligation, and unloading, using
abdominal heart transplantation.
2. Methods
Detailed description of methods can be found in Supplementary
material.
2.1 Animal models
The investigation conforms with the Guide for the Care and Use of
Laboratory Animals published by the US National Institutes of
Health (NIH Publication No. 85–23, revised 1996). Rat model of
chronic post-infarction cardiomyopathy was used as it is a well
established reproducible model of dysfunction.22,23 Syngeneic rat
strains avoid the need for immunosuppression after abdominal
transplantation. Therefore, male Lewis rats (200–300 g) were used
for all experiments. HF was induced by permanent LCA ligation as
previously described.22,23 Sham operated animals underwent left
thoracotomy and the needle was passed under the LCA and
removed without ligation. Change in LV function was assessed by
transthoracic echocardiography (Acuson Sequoia
TM
256; Acuson,
USA) over a period of 4–6 weeks, as previously described.24
To test the effect of clenbuterol in HF, Sham and HF animals
received an osmotic minipump (Model 2001, Alzet) containing clen-
buterol (2 mg/kg body weight/day) or normal saline (Sal) for 7 days
(Sham þ Sal, HF þ Sal or HF þ Clen), implanted subcutaneously.
To test the effects of mechanical unloading (UN), the failing
hearts were heterotopically transplanted25 into the abdomen of
control Lewis rats and the recipients then received an osmotic mini-
pump containing clenbuterol or Sal for 7 days (HF þ UN þ Sal or
HF þ UN þ Clen). Briefly the failing heart was removed from the
donor rat following cardioplegic arrest and the donor aorta was
anastamosed to the recipient abdominal aorta and the donor pul-
monary artery to the recipient inferior vena cava.
2.2 Ex vivo left ventricular function assessment
Ex vivo LV function of the transplanted heart was assessed by
measuring the pressure–volume relationship using an intra-
ventricular balloon as described previously.26 Hearts were perfused
with normal Tyrode (NT) solution at 378C on a Langendorff apparatus
and paced with platinum electrodes on the right ventricle to main-
tain a heart rate of 300 bpm.
2.3 Cardiomyocyte studies
LV myocytes were isolated following a previously described
method27 using collagenase (1 mg/mL, Worthington) and hyaluroni-
dase (0.6 mg/mL, Sigma) for 8–10 min. All cellular experiments
were performed at 378C, within 7–8 h of cell isolation. Cell size
was assessed from digital images of the cardiomyocytes. The pro-
jected two-dimensional area for each cell was measured using
ImageJ software (NIH, USA).
2.3.1 Sarcomere shortening and cytoplasmic
calcium measurement
Cells were superfused with a NT solution containing (in mM): NaCl
140, KCl 6, MgCl2 1, glucose 10, HEPES 10, CaCl2 1; pH 7.4, field-
stimulated at 1 Hz and illuminated by red light (wavelength of
.600 nm), enabling the cardiomyocyte in the field of view to be
visualized for simultaneous measurement of Indo-1 fluorescence
(Indo-1 AM) and sarcomere shortening using a Ionoptix system
(Ionoptix Corporation, USA) as described in data supplement. Sarco-
plasmic reticulum (SR) Ca2þ content was assessed by rapid appli-
cation of 20 mM caffeine and amplitude of caffeine-induced
Indo-1 transient taken as an index of SR Ca2þ content (see Sup-
plementary material for protocol). Time constant (t) of the transi-
ent was assessed by fitting a mono-exponential curve on the decay
phase to assess the contribution of sodium–calcium exchanger
(NCX) to Ca2þ extrusion.
2.3.2 Assessment of myofilament sensitivity to calcium
Cardiomyocyte myofilament sensitivity to Ca2þ was assessed using a
technique described by Bailey et al.28 Hysteresis loops were gener-
ated for all cells studied and a constant region of the declining
phase of the loop (the region between 20 and 80% from the peak
of the sarcomere shortening) was selected and the slope value of
this line was calculated by fitting a linear regression line. Only
slope values of the regression lines with a goodness of fit (r2)
greater than 0.8 were used for this analysis and data from each
treatment group were compared to assess changes in myofilament
sensitivity to Ca2þ.
2.3.3 Electrophysiological studies
Cardiomyocytes were superfused with NT solution. Action potentials
(APs) were measured in current-clamp mode using 30 MV resist-
ance pipettes (containing (in mM) KCl 2000, HEPES 5, EGTA 0.1;
pH 7.2) using a 1 ms, 1.2–1.4 nA pulse. For the measurement of
NCX current (INCX), cells were superfused with a solution containing
(in mM) NaCl 140, HEPES 10, glucose 10, MgCl2 1, CaCl2 1, CsCl 6;
0.01 strophanthidin; 0.01 nifedipine; pH 7.4. The pipette-filling sol-
ution contained (in mM): CsCl 45, HEPES 20, MgCl2 11, Na2ATP 10,
CsOH 100, EGTA 50, CaCO3 25; pH 7.2. Pipette resistance was
2.3–3.5 MV. A 3 s descending ramp was applied from þ80 to
2120 mV at 0.1 Hz, from a holding potential of 240 mV. The INCX
was taken as the 5 mM Ni2þ-sensitive component. For the measure-
ment of L-type calcium current (ICa,L), the same hardware configur-
ation and pipette-filling solution, as for AP were used, but in
voltage-clamp mode as previously reported.29,30 Current–voltage
(I–V) relationships for ICa,L were built using 450 ms depolarization
steps from a holding potential of 240 mV (range 245 to þ50 mV,
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in 5 mV increments). The measured current is nifedipine-sensitive
and 4-aminopyridine-insensitive, hence attributable to ICa,L. To
study time-dependent inactivation, a bi-exponential of the ICa,L
measured at 0 mV was fitted to the decay, and fast and slow com-
ponents of ICa,L inactivation identified (tfast and tslow). The voltage-
dependent steady-state activation profile (G/GMAX) and steady-state
inactivation (F/FMAX) of the ICa,L was studied as previously
described.31 All data were analysed using Clampfit& software
(Axon Instruments, CA, USA).
2.4 Gene expression analysis
RT-PCR was performed as described previously32 (see Supplementary
material). Primers and standard Taqman probes for a- and b-myosin
heavy chain (MHC) were designed in-house using Primer Express v.1 5
(a-MHC: Forward primer: 50-caaactcatggccacactcttct-30, reverse
primer: 50-ggaaggatgagcctttcttcttg-30, probe: 50-FAM-ccactgt-
caccggtatcagcagaagcata -30. b-MHC: Forward primer: 50-agctcctaag-
taatctgt ttgccaa-30, reverse primer: 50-aaaggatgagcctttctttgct-30,
probe 50-FAM-cttgtctacaggtgcatcagctccagcat-30). Data were ana-
lysed using the comparative Ct method with target gene expression
normalized to 18S ribosomal RNA levels.
2.5 Statistical analysis
Statistical comparison of data was performed using one-way analysis
of variance followed by Newman–Keuls post hoc test for individual
significant differences or Student’s t-test where appropriate. All
statistical analyses were performed using Prism 4 software (Graph-
Pad Software, Inc.) and P , 0.05 was considered significant. Data
are expressed as mean+SEM [n], where n is the number of cells
unless otherwise specified.
3. Results
3.1 The effects of clenbuterol on left ventricular
function of failing hearts in vivo
LV function of failing and sham operated animals, treated
with clenbuterol or saline, was assessed in vivo by echocar-
diography. LCA ligation produced LV dysfunction after 4–6
weeks at whole-heart level characterized by reduced LVEF,
reduced LV fractional shortening, LV wall thinning, and LV
chamber dilation on echocardiography (Figure 1B and D,
Table 1). Clenbuterol treatment of failing hearts increased
LVEF by 16%, increased LV fractional shortening by 6%,
and improved thickening of the viable posterior wall by
20% (Figure 1C and D, Table 1). These results indicate
that clenbuterol affects LV function of failing hearts.
3.2 The effects of clenbuterol on left ventricular
function ex vivo
LV function of normally loaded and mechanically unloaded
failing hearts, treated with clenbuterol or saline, was
assessed by ex vivo pressure–volume relationship studies.
LCA ligation reduced LV developed pressure and dP/dTmax
(Figure 1E and F). Clenbuterol treatment or mechanical
unloading alone did not affect these parameters but the
combination of both clenbuterol treatment and mechanical
unloading of failing hearts improved LV dP/dTmax (Figure 1G
and H ). These results indicate that the combination of clen-
buterol and mechanical unloading enhances LV functional
recovery of failing hearts.
3.3 The effects of clenbuterol on the
unloading-induced cell size reduction
Two-dimensional cell surface area, length, and width of LV
cardiomyocytes from all experimental groups were assessed
by planimetry. After LCA ligation, cardiomyocyte hypertro-
phy developed, as shown by an increase in cell surface
area ((mm2) Sham þ Sal 3251+64 [173], HF þ Sal 4129+
92 [106]; P , 0.001), increase in length ((mm): Sham þ Sal
128+2 [173], HF þ Sal 147+2 [106]; P , 0.001) and
increase in width ((mm): Sham þ Sal 35+1 [173], HF þ Sal
40+1 [106]; P , 0.001). As shown in Figure 2, clenbuterol
treatment alone did not further increase cell size. Mechan-
ical unloading alone reduced cell size to normal values (cell
area (mm2): Sham þ Sal 3251+64 [173] vs. HF þ UN þ Sal
3276+63 [181]; P ¼ NS) but clenbuterol treatment during
unloading limited this effect (cell area (mm2): HF þ UN þ
Sal 3276+63 [181], HF þ UN þ Clen 3547+59 [232]; P ,
0.01; HF þ Sal vs. HF þ UN þ Clen; P , 0.001). These
results indicate that clenbuterol limits unloading-induced
cell size reduction and supports the rationale of its use to
limit unloading-induced myocardial atrophy.
3.4 The effects of clenbuterol on cardiomyocyte
contractility
Cardiomyocyte contractility was assessed during field-
stimulation by real time changes of the sarcomere length.
Sarcomere shortening and relaxation were impaired after
LCA ligation (Figure 3A, Table 2) and were unaffected by
mechanical unloading alone (Figure 3C, Table 2). Clenbu-
terol treatment alone or in combination with mechanical
unloading improved sarcomere shortening and relaxation
(Figure 3BandD, Table 2). These results indicate that mech-
anical unloading alone did not affect the depressed cardio-
myocyte contractility but clenbuterol combined with
mechanical unloading enhanced functional recovery.
3.5 The effects of clenbuterol on calcium cycling
Cytoplasmic [Ca2þ] was assessed by measuring Indo-1 fluor-
escence ratio. Cardiomyocyte Ca2þ cycling, following LCA
ligation, was characterized by delayed Ca2þ release and
extrusion. However, the Ca2þ transient amplitude was
paradoxically increased (Figure 3A, Table 2). The increased
Ca2þ transient amplitude was accompanied by increased SR
Ca2þ content with delayed removal in caffeine-induced Ca2þ
transient (Table 2) suggesting a reduced NCX contribution to
Ca2þ extrusion from the cytoplasm. Clenbuterol treatment
alone did not affect Ca2þ transient amplitude or SR Ca2þ
content but normalized the delayed stimulation-induced
and caffeine-induced Ca2þ transient decline (Figure 3B,
Table 2). Mechanical unloading alone did not affect the
Ca2þ transient kinetics or SR Ca2þ content but induced a
faster decline of the caffeine-induced Ca2þ transient
(Table 2). The combination of clenbuterol treatment and
mechanical unloading of HF normalized Ca2þ handling at
cytoplasmic and SR levels (Figure 3D, Table 2). These
results indicate that the combination of clenbuterol and
mechanical unloading normalized the deranged cardiomyo-
cyte Ca2þ cycling.
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3.6 The effects of clenbuterol on myofilament
sensitivity to calcium
Myofilament sensitivity to Ca2þ was assessed by sarcomere
length-[Ca2þ]i relationship from simultaneously recorded
Indo-1 fluorescence changes and sarcomere shortening of
LV cardiomyocytes. The sarcomere shortening-Ca2þ transi-
ent hysteresis loops showed that less contractility was pro-
duced for the same [Ca2þ]i following LCA ligation,
Figure 1 Representative two-dimensional (top) and M-mode (bottom) echocardiography traces at mid-papillary level of a normal control heart (A), a failing
heart treated with saline showing a kinetic anterior scar and reduced contractility and thinning of posterior wall (B). A failing heart treated with clenbuterol
shows improved posterior wall contractility with unchanged anterior scar movement (C). Sham operated and heart failure animals treated with saline
showed no change in LVEF but clenbuterol treatment of failing hearts improved LVEF by 18% (D) (data shown in Table 1). (***P , 0.001 HF vs. HF þ Clen).
Pressure–volume relationship of sham operated and heart failure groups showing a reduced LV developed pressure (E) and dP/dTmax (F) of failing hearts
treated with saline. The combination of clenbuterol treatment and mechanical unloading improved dP/dTmax (H) but did not affect the LV developed pressure
(G). (*P , 0.05, **P , 0.01, ***P , 0.001 HF þ Sal vs. Sham þ Sal; §P , 0.05 HF þ UN þ Sal vs. HF þ UN þ Clen).
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suggesting reduced myofilament sensitivity to Ca2þ (Figure
4E, Table 2). Clenbuterol treatment alone or in combination
with mechanical unloading normalized this parameter.
Mechanical unloading did not affect the depressed myofila-
ment sensitivity to Ca2þ (Figure 4E, Table 2).
3.7 The effects of clenbuterol on action potential
prolongation
APD was assessed in current-clamp mode as described
above. Following LCA ligation, electrophysiological studies
demonstrated increased AP duration at all frequencies
compared to sham-operated controls (Figure 5A). Clenbu-
terol treatment did not affect the prolonged AP duration.
Mechanical unloading alone further prolonged the AP dur-
ation at higher stimulation frequency (APD90 at 5 Hz (ms):
HF þ Sal 44.7+3.0 [51], HF þ UN þ Sal 63.0+4.8 [26];
P , 0.01) (Figure 5A). The combination of clenbuterol
treatment and mechanical unloading normalized the pro-
longed AP duration in HF at all frequencies (Figure 5A).
These results indicate that clenbuterol combined with
mechanical unloading enhances recovery of deranged AP
properties.
3.8 The effects of clenbuterol on sodium–calcium
exchanger current
Clenbuterol normalized the delayed stimulation-induced
and caffeine-induced Ca2þ transient decline suggesting an
improved NCX contribution to Ca2þ extrusion from the cyto-
plasm. Therefore, INCX was measured to test if clenbuterol
affected the biophysical properties of NCX. The INCX was
unchanged at all voltages tested in cardiomyocytes from
hearts following LCA ligation and unaffected by clenbuterol
treatment alone (Figure 5B). Mechanical unloading reduced
INCX but this current was partially restored by clenbuterol
treatment (at þ80 mV (pA/pF): HF þ Sal 1.7+0.2 [30],
HF þ UN þ Sal 0.9+0.1 [25], HF þ UN þ Clen 1.6+0.3
[21]; HF þ Sal vs. HF þ UN þ Sal, P , 0.01; HF þ Sal vs.
HF þ UN þ Clen, P ¼ NS) (Figure 5B). These results indicate
that clenbuterol combined with mechanical unloading
improves NCX activity.
3.9 The effects of clenbuterol on L-type
calcium current
HF reduced peak ICa,L (Figure 6B) and resulted in slower
inactivation times (Figure 6E and F) which may partially
account for delayed Ca2þ release of the Ca2þ transient and
the prolonged APD90, respectively. Clenbuterol treatment
alone or in combination with the mechanical unloading did
not affect the ICa,L properties. Mechanical unloading alone
of failing hearts did not affect the peak ICa,L but normalized
slower ICa,L inactivation times seen in HF (tfast (ms): Sham þ
Sal 7.2+0.6 [43], HF þ UN þ Sal 5.5+0.4 [23]; P ¼ NS;
tslow (ms): Sham þ Sal 31.2+2.0 [43], HF þ UN þ Sal
27.3+2.0 [23]; P ¼ NS) (Figure 6E and F). These results
indicate that clenbuterol does not affect L-type calcium
current.
3.10 The effects of clenbuterol on myosin heavy
chain isoform changes
HF33 and mechanical unloading34 are known to induce a shift
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changes in the myofilament sensitivity to Ca2þ. In this study,
we show that clenbuterol normalizes the depressed myofila-
ment sensitivity to Ca2þ (Figure 4E). To clarify this point,
gene expression of a- and b-MHC were measured by
RT-PCR. There was a reduction in a-MHC RNA expression in
HF, which was further reduced by mechanical unloading
((relative mRNA expression) Sham þ Sal 1.58+0.14,6 HF þ
Sal 0.93+0.06;6 P , 0.01; HF þ UN þ Sal 0.31+0.135 vs.
HF þ Sal; P , 0.001). b-MHC expression was unchanged in
HF and mechanical unloading. The ratio of a-MHC/b-MHC
confirmed a reduction in relative a-MHC expression in HF
and mechanical unloading ((relative mRNA expresion)
Sham þ Sal 2.05+0.31,6 HF þ Sal 0.83+0.25;6 P , 0.05;
HF þ UN þ Sal 0.14+0.055 vs. HF þ Sal; P , 0.05). Clenbu-
terol treatment had no further effect on the relative a-MHC
isoform expression changes ((relative mRNA expresion) HF þ
Sal vs. HF þ Clen 0.63+0.12;5 P ¼ NS; HF þ UN þ Sal vs.
HF þ UN þ Clen 0.15+0.05;4 P ¼ NS). This suggests that
the improved myofilament sensitivity to Ca2þ seen after
clenbuterol treatment is unlikely to be due to changes in
MHC isoform expression.
4. Discussion
This study demonstrates that the depressed whole-heart and
cellular contractile function observed in HF can be improved
by chronic administration of b2-AR agonist clenbuterol. At
whole-heart level in vivo clenbuterol improves LVEF and,
when combined with mechanical unloading, it also improves
dP/dTmax ex vivo. At a cellular level, depressed sarcomere
contractility is restored to normal values in HF by clenbu-
terol treatment, with or without mechanical unloading.
Clenbuterol affects cell size, EC coupling, ion channel func-
tion and AP properties but the cellular functional improve-
ment can be ascribed particularly to the normalization of
myofilament sensitivity to Ca2þ. Mechanical unloading
alone has no effects on the depressed sarcomere shortening
or whole-heart function.
4.1 b2-AR agonists and heart failure
HF causes derangements of b-AR signalling pathways.35
There is evidence that the b2-AR-Gi subtype specific
Figure 2 Representative pictures of left ventricular myocytes showing changes induced by heart failure, mechanical unloading and clenbuterol treatment (A).
Heart failure induced myocyte hypertrophy, indicated by an increased cell area (B), width (C) and length (D). Clenbuterol treatment limited unloading-induced
normalization of cell area by retaining cell length. (**P , 0.01, ***P , 0.001).
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stimulation has cardioprotective effects and beneficial func-
tional consequences in rodent ischaemic cardiomyopathy
and may also be enhanced when combined with b1-AR block-
ade.19,23,36 In the present study, we demonstrate whole-
heart and cellular function improvement with the b2-AR
agonist clenbuterol without mechanical unloading. Xydas
et al.19 have shown an improvement in ex vivo end diastolic
pressure–volume relationship in failing hearts treated for 9
weeks with clenbuterol compared to b1 blocker metoprolol.
In a preliminary study, we have found that clenbuterol pre-
dominantly activates the b2-AR-Gi pathway
37 and this may
explain the cardioprotective effects observed. More
studies are required to elucidate this point. The role of
b2-AR stimulation during mechanical unloading is also
complex. Although mechanical unloading is known to
restore b-AR responsiveness and density in HF38 and increase
b2-AR mRNA expression,
39 it has been shown that adenoviral
gene transfer of a b2-AR transgene in unloaded rabbit hearts
further improved myocardial function.40 In the present
study, the combination of b2-AR agonist clenbuterol and
mechanical unloading improved whole-heart and cardiomyo-
cyte contractile function, affected cell morphology, normal-
ized deranged Ca2þ cycling, myofilament sensitivity to Ca2þ,
AP duration and NCX current density. Our study further sup-
ports the use of b2-AR stimulation during mechanical
unloading to improve myocardial function.
The ability of clenbuterol to induce structural changes to
the myocardium is controversial. Burniston et al.41 have
shown a dose-dependent, b1-AR mediated, clenbuterol-
induced myocardial apoptosis, necrosis, and collagen
content in the heart and skeletal muscle of the rat after
clenbuterol administration. We did not selectively block
the b1-AR in our study but it is possible to predict that this
strategy would further improve the beneficial effects of
clenbuterol during mechanical unloding in HF. On the basis
of the above rationale to maximize the b2-AR mediated ben-
eficial effects of clenbuterol during mechanical unloading,
bisoprolol a selective b1 blocker, is used in combination
with clenbuterol in the patients treated with LVADs.11
Other studies have shown that clenbuterol administration
has a beneficial effect on fibrosis and apoptosis. Wong
et al. have shown that clenbuterol administration in con-
junction with pressure overload by aortic banding in rats
increases LV mass with less fibrosis16 and collagen
content15 than banding alone. George et al.12 report no
change in collagen content in HF patients treated with clen-
buterol during mechanical unloading by LVAD.
4.2 Clenbuterol and unloading-induced myocyte
atrophy
Myocardial atrophy is an important consequence of mechan-
ical unloading and has been demonstrated in both human7
and animal42 studies. This is likely to be the main limiting
factor to improve myocardial recovery and forms the basis
for use of clenbuterol in patients treated with LVADs in
order to improve explantation rate for ‘bridge to recov-
ery’.10 We have shown in a previous study that clenbuterol
increases cardiomyocyte size in normal hearts13 and, in
this study, limits cell size reduction after mechanical
unloading in HF. In contrast, Tsuneyoshi et al.20 found that
clenbuterol could not prevent atrophy during mechanical
unloading of a normal rat heart for 2 weeks. This may
Figure 3 Simultaneously acquired sarcomere shortening and Indo-1 transi-
ents showing defective EC coupling in heart failure (A). Clenbuterol treat-
ment, with and without mechanical unloading, improved myocyte
contractility and Ca2þ transient kinetics (B–D). Arrows highlight statistically
significant differences between groups (data shown in Table 2).
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suggest that myocyte hypertrophy, induced by HF, may be a
prerequisite for the effects of clenbuterol during mechan-
ical unloading. It should be noted that we only assessed
unloading after 1 week. It is known that longer duration of
unloading in failing human7 and animal34 hearts can deleter-
iously affect whole-heart and cardiomyocyte function,
despite regression of myocyte hypertrophy. Testing
whether clenbuterol administration is beneficial when used
during longer periods of mechanical unloading of failing
hearts would be of interest. Clenbuterol may have an
important role in providing an early phase of protection,
delaying the onset or preventing unloading-induced
atrophy. To elucidate these points, further studies are
required.
We have shown that clenbuterol treatment during unload-
ing (HF þ UN þ Clen) limits cardiomyocyte atrophy by a pre-
ferential retention of cell length than width. This may
indicate a different form of hypertrophy induced by clenbu-
terol, which has been proposed to be more ‘physiologi-
cal’.14–17,43,44 In addition, in the unloaded myocardium,
Figure 4 Simultaneously acquired sarcomere shortening and Indo-1 transient traces (A) were used to generate hysteresis loops (B) showing the relationship of
sarcomere length and cytoplasmic Ca2þ concentration, measured by Indo-1 (r.u.—ratio units). The slope of a regression line, fitted through the linear portion of
the loop (C, D), was used as a measure of myofilament sensitivity to Ca2þ. Clenbuterol treatment improved the depressed myofilament sensitivity to Ca2þ in heart
failure, with and without mechanical unloading (E, data shown in Table 2). (*P , 0.05, **P , 0.01, ***P , 0.001).
Table 2 Contractile and calcium handling parameters in experimental groups
Sham þ Sal HF þ Sal HF þ Clen HF þ UN þ Sal HF þ UN þ Clen
1 Hz Sarcomere shortening
Baseline SL (mm) 1.63+0.02 [46] 1.59+0.01 [68]* 1.64+0.01 [69]†† 1.59+0.01 [38] 1.64+0.01 [50]††,§
Amplitude (mm) 0.08+0.01 [46] 0.07+0.01 [68]* 0.1+0.01 [69]††† 0.07+0.01 [38] 0.1+0.01 [50]†††,§§§
Time to peak (ms) 86.9+3.3 [46] 102.6+2.6 [68]*** 84.9+2.3 [69]††† 97.8+2.7 [38] 71.9+1.7 [50]†††,§§§
Time to 50% relaxation (ms) 70.5+5.7 [42] 91.2+6.1 [65]* 53.6+2.4 [68]††† 90.0+6.2 [38] 46.0+2.2 [50]†††,§§§
1 Hz Ca2þ transient
Baseline (Indo-1 ratio units) 0.31+0.01 [45] 0.33+0.01 [67]** 0.33+0.01 [69] 0.31+0.01 [38] 0.32+0.01 [48]
Amplitude (Indo-1 ratio units) 0.12+0.01 [45] 0.15+0.01 [67]** 0.14+0.01 [69] 0.14+0.01 [38] 0.11+0.01 [48]†††,§§
Time to peak (ms) 33.3+1.1 [45] 36.4+0.6 [67]** 34.6+0.7 [69] 34.9+1.1 [38] 31.2+0.7 [47]†††,§§
Time to 50% decay (ms) 70.9+1.5 [45] 75.4+1.4 [66]* 68.5+1.1 [69]††† 74.3+1.9 [38] 62.5+1.4 [48]†††,§§§
Indo-1 decay, t (ms) 76.4+2.9 [45] 88.2+3.4 [66]* 65.8+2.2 [69]††† 83.1+3.8 [38] 58.5+1.3 [48]†††,§§§
Caffeine induced Ca2þ transient
SR Ca2þ content (Indo-1 ratio units) 0.11+0.01 [29] 0.14+0.01 [43]** 0.14+0.004 [41] 0.14+0.01 [26] 0.11+0.01 [34]†,§
Indo-1 decay, t (s) 1.21+0.08 [22] 1.44+0.06 [42]* 1.21+0.07 [35]†† 1.20+0.07 [23]† 1.14+0.07 [26]††
Myofilament sensitivity to Ca2þ
Slope value (mm/ratio unit) 2.23+0.27 [35] 1.65+0.12 [66]* 2.36+0.18 [69]†† 1.42+0.13 [38] 2.13+0.2 [52]†,§
*P , 0.05, **P , 0.01, ***P , 0.001 HF þ Sal vs. Sham þ Sal; †P , 0.05, ††P , 0.01, †††P , 0.001 vs. HF þ Sal; §P , 0.05, §§P , 0.01, §§§P , 0.001, HF þ UN þ
Sal vs. HF þ UN þ Clen (data in [] indicates number of cells studied).
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there is an association with the atrophic response of the
myocytes and this can explain the morphological differences
observed. More studies are required to investigate this
point.
4.3 Clenbuterol and excitation–contraction
coupling
Twitch Ca2þ transient amplitude and SR Ca2þ content are
generally reduced in human45 and animal models of HF.46
However, some studies in animal models have also shown
unchanged47 or increased22 Ca2þ transient amplitude with
altered contractility. As in the present study, Loennechen
et al.22 have shown an increased diastolic and systolic
Ca2þ transient at 1, 4, and 13 weeks post-infarction in a
rat model. Vahl et al.48 have demonstrated the after-load
dependence of the Ca2þ transient amplitude in human HF.
They attribute this to an increased dissociation of Ca2þ
from the contractile proteins, defective Ca2þ reuptake of
the SR or an increased Ca2þ inflow via Ca2þ channels. The
differing results in Ca2þ transient kinetics in the above
studies may depend on the model of HF and experimental
Figure 5 Action potential duration was prolonged in heart failure and unaffected by clenbuterol treatment (A). Mechanical unloading of failing hearts further
prolonged action potential duration at higher stimulation frequency which was normalized by clenbuterol treatment. Clenbuterol normalized the
unloading-induced reduction of INCX current density (B). Inset showing the voltage-clamp protocol used.
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conditions. The paradoxical increased Ca2þ transient ampli-
tude and SR Ca2þ content with reduced sarcomere shorten-
ing amplitude seen in our model of post-infarction
cardiomyopathy may indicate an intermediate stage in the
development of HF with pathological hypertrophy, reduced
contractile function and defective myofilament sensitivity
to Ca2þ.
An increased Ca2þ transient may result from a reduced
function of NCX and consequent increased Ca2þ load of the
SR in the presence of maintained SR Ca2þ uptake. The mech-
anisms by which NCX is involved in the improvement are
unclear. It is possible that NCX has a compensatory rather
than a causal role in the improvement observed. Other
Ca2þ regulatory mechanisms, such as SR Ca2þ uptake, and
factors that regulate NCX activity, such as [Naþ]i
49,50 and
phosphorylation,51 can be involved. NCX mediated-Ca2þ
extrusion was faster in unloaded myocytes with or without
clenbuterol. In the clenbuterol-treated group, the
Figure 6 ICa,L activation and inactivation properties were studied using the protocols A and C, respectively. Heart failure reduced peak ICa,L as shown by I–V
relationship (B) prolonged inactivation times (E, F) which were unaffected by clenbuterol treatment. Mechanical unloading normalized the prolonged inacti-
vation times with no additional affect by clenbuterol treatment. The conductance/conductancemax relationship of all groups was unchanged (D). (*P , 0.05,
**P , 0.01).
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biophysical properties of NCX (assessed as INCX) were directly
affected. More studies are required to investigate this point.
The prolongation of the AP in HF may also contribute to
the increased SR Ca2þ loading and increase the twitch
Ca2þ transient amplitude30 as seen in our study. Mechanical
unloading alone did not affect the deranged cardiomyocyte
contractility or Ca2þ cycling of failing hearts in our study.
This might be due to the short duration of unloading as
suggested by Ito et al.9
We found a delayed time course of both twitch and
caffeine-induced Ca2þ removal in myocytes from failing
hearts which was improved by clenbuterol treatment alone
and in combination with mechanical unloading. A number
of factors can explain this behaviour. In the group treated
with clenbuterol alone, the NCX contribution to Ca2þ
removal may be increased due to the changes in intracellu-
lar [Naþ] as discussed above. In the group with clenbuterol
and mechanical unloading, the shortening of the AP and
increased NCX current density could also be important.
Finally the contribution of the SR Ca2þ uptake, which has
not been addressed in this study, may also play an important
role.
4.4 Clenbuterol and myofilament sensitivity
to calcium
Abnormal myofilament function contributes significantly to
contractile dysfunction in chronic HF although its relative
importance compared to altered Ca2þ homeostasis is cur-
rently debated.52 In the model used in this study, we have
demonstrated depressed myofilament Ca2þ sensitivity. Clen-
buterol treatment normalized this depressed myofilament
Ca2þ sensitivity irrespective of whether it was associated
to mechanical unloading. This may be a key mechanism
involved in the ability of clenbuterol to improve contractile
function at cellular level. Our results suggest that the
improved myofilament sensitivity to Ca2þ seen after clenbu-
terol treatment is not due to the effects of clenbuterol on
MHC expression. It is possible that clenbuterol affects
other key mechanisms like the phophorylation states of
troponin-I and myosin binding protein-C.
One possible limitation in our study is that we have esti-
mated myofilament sensitivity to Ca2þ by assessing the
relationship between sarcomere shortening and Indo-1 fluor-
escence. We did not calibrate the fluorescence signals and
quantify cytoplasmic [Ca2þ]. Although this can be a possible
source of error, the relationship between Indo-1 fluor-
escence ratio and cytoplasmic [Ca2þ] is sufficiently linear
in the range of measurements reported (20–80% of Ca tran-
sients)53,54 to allow comparisons between groups.
4.5 Conclusions
In our study, clenbuterol affects cell size, EC coupling, ion
channel function, and AP properties and normalizes myofila-
ment sensitivity to Ca2þ. The combination of all the above
changes, rather than changes in a single parameter, may
lead to the improved cellular and whole-heart function.
The temporal and causal relationship of the changes in
relation to contractile functional improvement is a challen-
ging point that requires further studies.
In conclusion, the treatment of failing hearts with clenbu-
terol, alone or in combination with mechanical unloading,
improves LV function at whole-heart and cellular level.
This study supports the use of this drug in the strategy to
enhance recovery in HF patients treated with LVADs and
also begins to elucidate some of the possible cellular mech-
anisms responsible for the improvement in LV function.
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